Hale develops veterinary pharmaceuticals intended to provide effective treatment with safer profiles for companion animals.
Investment Funding
Last Funding Stage
Seed
Total Funding Amount
1.18M
Last Funding Amount
1.18M
Last Funding Date
19-04-2024
Startup Stage
Seed
Lead Investors
WNT Ventures, Callaghan Innovation
People
Founders
Leila de Koster
About
Hale Animal Health is developing a range of novel veterinary pharmaceuticals for companion animals. By offering new and improved treatments for pets, the company elevates the quality of life for every pet. Products are safe and effective, without any side effects.
Products
Product
Novel companion-animal pharmaceutical pipeline, including a cannabinoid-based medicine studied for canine arthritis.
Star Product
Canine arthritis medicine program – the most publicly documented clinical-development asset.
Demo Product or Complete Product?
Clinical-development stage; the company is advancing products toward commercialization.
Future Plan
Market Expansion
The 2026 raise was described as financing the company through its next development phase toward commercialization.
Investment Funding
Raised NZD 4 million in a 2026 capital round.
Something missing or incorrect on this page? Help us enrich this information
